Last reviewed · How we verify
dl-Methylphenidate plus Cannabidiol
dl-Methylphenidate plus Cannabidiol is a Combination therapy: sympathomimetic amine plus phytocannabinoid Small molecule drug developed by University of Florida. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) with anxiety or comorbid conditions. Also known as: Ritalin®, Epidiolex®.
dl-Methylphenidate increases dopamine and norepinephrine availability in the central nervous system, while cannabidiol modulates endocannabinoid signaling and has anti-inflammatory properties.
dl-Methylphenidate plus Cannabidiol is being studied for its potential drug interaction effects in healthy subjects. This combination is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism associated with dl-Methylphenidate.
At a glance
| Generic name | dl-Methylphenidate plus Cannabidiol |
|---|---|
| Also known as | Ritalin®, Epidiolex® |
| Sponsor | University of Florida |
| Drug class | Combination therapy: sympathomimetic amine plus phytocannabinoid |
| Target | Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a sympathomimetic amine that blocks the reuptake of dopamine and norepinephrine, enhancing attention and executive function. Cannabidiol (CBD) acts as a modulator of cannabinoid receptors and other targets (5-HT1A, TRPV1), providing anxiolytic and anti-inflammatory effects. The combination is designed to leverage methylphenidate's cognitive enhancement while CBD may mitigate potential anxiety or adverse effects from stimulant use.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) with anxiety or comorbid conditions
Common side effects
- Insomnia
- Appetite suppression
- Headache
- Dizziness
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dl-Methylphenidate plus Cannabidiol CI brief — competitive landscape report
- dl-Methylphenidate plus Cannabidiol updates RSS · CI watch RSS
- University of Florida portfolio CI
Frequently asked questions about dl-Methylphenidate plus Cannabidiol
What is dl-Methylphenidate plus Cannabidiol?
How does dl-Methylphenidate plus Cannabidiol work?
What is dl-Methylphenidate plus Cannabidiol used for?
Who makes dl-Methylphenidate plus Cannabidiol?
Is dl-Methylphenidate plus Cannabidiol also known as anything else?
What drug class is dl-Methylphenidate plus Cannabidiol in?
What development phase is dl-Methylphenidate plus Cannabidiol in?
What are the side effects of dl-Methylphenidate plus Cannabidiol?
What does dl-Methylphenidate plus Cannabidiol target?
Related
- Drug class: All Combination therapy: sympathomimetic amine plus phytocannabinoid drugs
- Target: All drugs targeting Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
- Manufacturer: University of Florida — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD) with anxiety or comorbid conditions
- Also known as: Ritalin®, Epidiolex®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing